These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15218425)

  • 41. Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
    Ahmad N; Zaidi A; Badar F; Maaz AU; Akram MS
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):49-56. PubMed ID: 20398038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center.
    Prakash G; Sharma A; Raina V; Kumar L; Sharma MC; Mohanti BK
    Ann Hematol; 2012 Oct; 91(10):1603-11. PubMed ID: 22584851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children.
    Patte C; Philip T; Rodary C; Zucker JM; Behrendt H; Gentet JC; Lamagnère JP; Otten J; Dufillot D; Pein F
    J Clin Oncol; 1991 Jan; 9(1):123-32. PubMed ID: 1985161
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
    Späth-Schwalbe E; Lange C; Genvresse I; Krüger L; Eucker J; Schweigert M; Sezer O; Budach V; Possinger K
    Anticancer Drugs; 2002 Apr; 13(4):395-403. PubMed ID: 11984085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Head and neck presentations of B-NHL and B-AL in children/adolescents: experience of the LMB89 study.
    Lervat C; Auperin A; Patte C; Méchinaud F; Leverger G; Nelken B; Bertrand Y; Baruchel A; Coze C; Munzer M; Lacombe MJ; Bergeron C
    Pediatr Blood Cancer; 2014 Mar; 61(3):473-8. PubMed ID: 23970385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
    Badowska W
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity].
    Karachunskiĭ AI; Miakova NV; Rumiantseva IuV; Timakov AM; Makhortykh TZh; Fechina LG; Shamardina AV; Dudkin SA; Lebedev VV; Varfolomeeva SR; Timofeeva VN; Herold R; Stakelberg A; Henze G; Rumiantsev AG
    Ter Arkh; 2007; 79(7):19-26. PubMed ID: 17802785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
    Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
    Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence and Risk Factors for Hypertension During Childhood Acute Lymphoblastic Leukemia Therapy.
    Malhotra P; Kapoor G; Jain S; Garg B
    Indian Pediatr; 2018 Oct; 55(10):877-879. PubMed ID: 29941701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of pediatric Burkitt lymphoma in Turkey.
    Celkan TT; Bariş S; Ozdemir N; Ozkan A; Apak H; Doğru O; Karaman S; Canbolat A; Ozdil M; Aki H; Adaletli I; Kurugoglu S; Hallac M; Yildiz I
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):e279-84. PubMed ID: 20736844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
    Aricò M; Conter V; Valsecchi MG; Rizzari C; Boccalatte MF; Barisone E; Messina C; De Rossi G; Lo Nigro L; Pession A; Locatelli F; Micalizzi C; Basso G
    Haematologica; 2005 Sep; 90(9):1186-91. PubMed ID: 16154841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
    Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
    Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
    Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
    Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
    Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
    Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lymphoblastic Lymphoma Presenting as Bilateral Ovarian Mass in an Adolescent Girl.
    Narayanan G; Soman LV
    J Pediatr Adolesc Gynecol; 2017 Jun; 30(3):435-437. PubMed ID: 27965123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.